Updated Recommendations on Nonstatin Therapies for Managing LDL-C: Health System Considerations for ASCVD Risk Management
Evolving Recommendations for Nonstatin Use in Patients with ASCVD
Key Treatment Considerations and Takeaways from the 2022 Expert Consensus Decision Pathway
Systematically Implementing Innovative Care Models in Lipid Management
Overcoming Barriers and Improving Access to Nonstatin Therapies
Final Thoughts on Updated Expert Consensus Decision Pathway Recommendations
Meet the Speakers
MODERATOR:
Tyler Gluckman, MD, MHA, FACC, FAHA, FASPC
Medical Director
Center for Cardiovascular Analytics,
Research, and Data Science
Providence Heart Institute
Portland, OR
Nihar Desai, MD, MPH
Associate Professor, Yale School of Medicine
Vice Chief, Cardiovascular Medicine
New Haven, CT
Seth Martin, MD, MHS
Associate Professor of Medicine (Cardiology)
Johns Hopkins University School of Medicine
Baltimore, MD
Alan S. Brown, MD, MHA, FACC, MNLA
Director, Division of Cardiology and the Lipid Clinic, Advocate Lutheran General Hospital Clinical Associate Professor, Loyola University Chicago Stritch School of Medicine Past President, National Lipid Association
Downers Grove, IL
Panelists were compensated for their time. Insights shared reflect individual experiences and perspectives.
PROGRAM OBJECTIVES
In this on-demand broadcast, the experts will:
Examine the role of nonstatin therapies for LDL-C in the management of ASCVD, including opportunities to address gaps in care for improving uptake of optimal medication management
Discuss system-level considerations when implementing new lipid management recommendations to promote population health initiatives aimed at reducing CV risk in ASCVD patients and improving health outcomes
©2022 Amgen Inc. All rights reserved.
USA-145-84201 12/22